-
Original Article
-
Korean J Med. 2006;71(4):426-430.
- 증례:Clopidogrel에 의해 유발된 호중구 감소증 1예
-
김민웅, , , , , ,
-
- A case of clopidogrel induced neutropenia
-
Min Woong Kim, Ji Hoon Yoon, Chi Hoon Kim, Hwa Mi Kang, Jung Ho Park, Jo Gyeong Im, Tae Ik Kim
-
고려대학교 의과대학 내과학교실
-
- Abstract
- Clopidogrel is an oral agent that blocks ADP receptor-mediated platelet aggregation. Clopidogrel
along with aspirin was shown by the CURE trial to result in a 20% relative reduction of
cardiovascular death, myocardial infarction or stroke. Ticlopidine has been shown to reduce the
incidence of stent thrombosis compared with warfarin, but it may cause serious hematological side
effects. However, the reported neutropenia has been similar to clopidogrel and aspirin treatment
groups (0.01 vs 0.17%, respectively) with corresponding rates (0.05 vs 0.04%, respectively) of severe
neutropenia. We treated a 72-year-old female patient with severe neutropenia who underwent
percutaneous coronary intervention with drug-eluting stent placement and had no neutrophils in the
peripheral blood at 11 days after clopidogrel use. Therefore, clinicians should be alerted to the
possibility of severe neutropenia with clopidogrel treatment.(Korean J Med 71:426-430, 2006)
Key Words : Clopidogrel, Neutropenia
Keywords :
